세계의 생명과학 분석 시장 : 유형별, 컴포넌트별, 용도별, 최종사용자별, 지역별 - 예측(-2030년)

The global life science analytics market is projected to reach USD 68.81 billion by 2030 from USD 40.03 billion in 2025, at a CAGR of 11.4% during the forecast period. The market is anticipated to grow due to the complexity and diversity of big data in the life sciences sector. There is an increasing demand for advanced analytical solutions for various applications across the industry, including research and development, commercialization (such as market access, pricing, and sales and marketing), and safety. Additionally, the market has grown because of the need for better data standardization in the life sciences and healthcare industries. However, challenges to market growth include inadequate IT infrastructure and a reluctance to adopt analytics solutions in emerging economies.

"The software-as-a-service (SaaS) subsegment is expected to register the highest growth during the forecast period."

The life science analytics software segment is further segmented into on-premise, cloud-based, and software-as-a-service. The software-as-a-service (SaaS) segment is expected to register the highest growth during the forecast period. The growth of the SaaS segment can be attributed to the ample number of advantages offered by this model, such as the seamless integration of data from various cloud silos, unlimited user access from remote locations, low maintenance costs, high security, privacy, easy accessibility, no upfront capital investment for hardware, and extreme capacity flexibility and optimized resource utilization. Moreover, several applications offered by the SaaS model, spanning areas such as accounting, performance monitoring, and communication through webmail and instant messengers, further contribute to the segment's growth.

"Pharmaceutical & biotechnology companies are expected to dominate the life science analytics market during the forecast period."

Pharmaceutical & biotechnology companies, medical device companies, research institutes, and outsourced life science organizations make up the end-user segments of the life science analytics market. In 2024, pharmaceutical & biotechnology companies accounted for a significant share of the life science analytics market, by end user. This segment is also expected to register the highest growth during the forecast period. The prominent position & high growth of this segment are due to the increasing R&D expenditure of pharma & biotech companies, the increasing use of analytics for research & development processes, the growing importance of analytics in pharmacovigilance, the need to accelerate drug discovery and optimize clinical trials, and the need to enhance regulatory compliance through data-driven insights. Moreover, the push for personalized medicine and precision therapeutics and the integration of AI and machine learning further strengthen the value of analytics in the pharma & biotech industry.

"Asia Pacific is expected to register the highest market growth during the forecast period."

The life science analytics market is bifurcated into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to register the highest growth during the forecast period. The high growth of this region can be attributed to the presence of a large and growing patient population in the region, the increasing need for innovative therapies, the emergence of big data in healthcare, increasing spending on HCIT infrastructure, and the shifting focus of various market players on emerging countries in the region. Government initiatives to promote the adoption of digital & technologically enabled solutions across the life science industry and the significant focus on integrating sophisticated technologies across workflows also contribute to market growth.

The breakdown of primary participants is as mentioned below:

• By Company Type: Tier 1 (32%), Tier 2 (44%), and Tier 3 (24%)
• By Designation: Directors (30%), Managers (34%), and Others (36%)
• By Region: North America (40%), Europe (28%), Asia Pacific (20%), Latin America (7%), and the Middle East & Africa (5%)

List of Companies Profiled in the Report

• Oracle (US)
• Merative (formerly IBM) (US)
• SAS Institute (US)
• Accenture (Ireland)
• IQVIA (US)
• Cognizant (US)
• Wipro (India)
• Veradigm (US)
• Optum (US)
• Microsoft (US)
• MaxisIT (US)
• ExlService Holdings (US)
• Inovalon (US)
• CitiusTech (US)
• Saama (US)
• Axtria (US)
• Clarivate (UK)
• ThoughtSphere (US)
• ThoughtSpot (US)
• Salesforce (US)
• Google LLC (US)
• Amazon Web Services, Inc. (US)
• Veeva Systems (US)
• Elsevier (Netherlands)
• Komodo Health, Inc. (US)

Research Coverage:

The report provides an analysis of the life science analytics market and aims to estimate the market size and future growth potential of various segments based on type, component, application, end user, and region. It also examines factors affecting market growth, including drivers, opportunities, and challenges. The report evaluates the opportunities and challenges for stakeholders and explores micromarkets in terms of their growth trends, prospects, and contributions to the overall life science analytics market. Additionally, the report forecasts the revenue of market segments across five major regions. It includes a competitive analysis of the key players in the market, accompanied by their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

• Analysis of key drivers (rising pressure to curb healthcare spending, need for improved data standardization, technological advancements in analytical solutions, heterogeneity and complexity of big data in life sciences, growing adoption of analytical solutions in clinical trials, and increasing R&D expenditure in pharmaceutical & biotechnology companies), restraints (high implementation costs of advanced analytical solutions and data privacy concerns), opportunities (growing focus on value-based care, use of analytics in precision & personalized medicine, big data analytics for R&D productivity, and growing adoption of cloud-based analytics), and challenges (issues associated with data integration, shortage of skilled personnel, and reluctance to adopt life science analytics solutions in emerging countries) are factors contributing the growth of the life science analytics market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the life science analytics market.
• Market Development: Comprehensive information on the lucrative emerging markets, type of solution, component, deployment model, industry, and region.
• Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, and investments in the life science analytics market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global life science analytics market such as Oracle (US), Merative (formerly IBM) (US), SAS Institute (US), Accenture (Ireland), IQVIA (US), Cognizant (US), Wipro (India), Veradigm (US), and Optum (US)

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 LIFE SCIENCE ANALYTICS MARKET OVERVIEW
• 4.2 LIFE SCIENCE ANALYTICS MARKET, BY REGION
• 4.3 NORTH AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY END USER AND COUNTRY
• 4.4 LIFE SCIENCE ANALYTICS MARKET: GEOGRAPHIC SNAPSHOT
• 4.5 LIFE SCIENCE ANALYTICS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising pressure to curb healthcare spending
    • 5.2.1.2 Need for improved data standardization
    • 5.2.1.3 Technological advancements in analytical solutions
    • 5.2.1.4 Heterogeneity and complexity of big data in life sciences
    • 5.2.1.5 Growing adoption of analytical solutions in clinical trials
    • 5.2.1.6 Increasing R&D expenditure in pharmaceutical & biotechnology companies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High implementation costs of advanced analytical solutions
    • 5.2.2.2 Data privacy concerns
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing focus on value-based care
    • 5.2.3.2 Use of analytics in precision & personalized medicine
    • 5.2.3.3 Big data analytics for R&D productivity
    • 5.2.3.4 Growing adoption of cloud-based analytics
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Issues associated with data integration
    • 5.2.4.2 Shortage of skilled personnel
    • 5.2.4.3 Reluctance to adopt life science analytics solutions in emerging countries
• 5.3 INDUSTRY TRENDS
  • 5.3.1 GROWING ADOPTION OF ANALYTICS IN COMMERCIAL OPERATIONS
  • 5.3.2 LEVERAGING DATA & ANALYTICS TO ACCELERATE DRUG DISCOVERY & DEVELOPMENT
  • 5.3.3 FOCUS ON REAL-TIME DATA ANALYTICS
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Artificial intelligence and machine learning
    • 5.4.1.2 Big data analytics
    • 5.4.1.3 Quantum computing
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Bioinformatics tools
    • 5.4.2.2 Internet of Things
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Blockchain
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 PORTER'S FIVE FORCES ANALYSIS
  • 5.7.1 THREAT OF NEW ENTRANTS
  • 5.7.2 THREAT OF SUBSTITUTES
  • 5.7.3 BARGAINING POWER OF SUPPLIERS
  • 5.7.4 BARGAINING POWER OF BUYERS
  • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.8.2 BUYING CRITERIA
• 5.9 CASE STUDY ANALYSIS
  • 5.9.1 NOVARTIS USES MULTI-CLOUD DATA ANALYTICS PLATFORM TO OPTIMIZE OPERATIONS AND ACCELERATE INNOVATION
  • 5.9.2 SAS VISUAL ANALYTICS HELPS MAXIMIZE PROFITABILITY THROUGH PRESCRIPTIVE ANALYTICS & DATA VISUALIZATION
  • 5.9.3 STREAMLINING REGULATORY MONITORING AND IMPACT ASSESSMENTS: GEDEON RICHTER'S PARTNERSHIP WITH CLARIVATE
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.2 NORTH AMERICA
  • 5.10.3 EUROPE
  • 5.10.4 ASIA PACIFIC
  • 5.10.5 MIDDLE EAST & AFRICA
  • 5.10.6 LATIN AMERICA
• 5.11 PRICING ANALYSIS
  • 5.11.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY APPLICATION
  • 5.11.2 AVERAGE SELLING PRICE, BY REGION
• 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.14 PATENT ANALYSIS
  • 5.14.1 PATENT PUBLICATION TRENDS
  • 5.14.2 JURISDICTION ANALYSIS: TOP APPLICANT
  • 5.14.3 MAJOR PATENTS
• 5.15 END USER ANALYSIS
  • 5.15.1 UNMET NEEDS
  • 5.15.2 END-USER EXPECTATIONS
• 5.16 LIFE SCIENCE ANALYTICS BUSINESS MODELS
  • 5.16.1 SUBSCRIPTION-BASED MODEL
  • 5.16.2 SAAS MODEL
  • 5.16.3 PAY-PER-USE/USAGE-BASED MODEL
  • 5.16.4 ENTERPRISE LICENSING
  • 5.16.5 FREEMIUM MODEL
  • 5.16.6 ENTERPRISE LICENSING
  • 5.16.7 CONCURRENT LICENSING
  • 5.16.8 CONSULTING SERVICES MODEL
  • 5.16.9 PARTNERSHIP/REVENUE-SHARING MODEL
  • 5.16.10 HYBRID MODELS
• 5.17 INVESTMENT & FUNDING SCENARIO
• 5.18 IMPACT OF AI/GENERATIVE AI ON LIFE SCIENCE ANALYTICS MARKET
  • 5.18.1 TOP USE CASES & MARKET POTENTIAL
    • 5.18.1.1 Key use cases
  • 5.18.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
    • 5.18.2.1 Case study 1: Knowledge mining for a global biopharmaceutical company
    • 5.18.2.2 Healthcare analytics market
  • 5.18.3 USER READINESS AND IMPACT ASSESSMENT
    • 5.18.3.1 User readiness
      • 5.18.3.1.1 Pharmaceutical & biotechnology companies
      • 5.18.3.1.2 Medical device companies
      • 5.18.3.1.3 Research centers
      • 5.18.3.1.4 Outsourced life science organizations
    • 5.18.3.2 Impact assessment
      • 5.18.3.2.1 User A: Pharmaceutical & biotechnology companies
        • 5.18.3.2.1.1 Implementation
        • 5.18.3.2.1.2 Impact
      • 5.18.3.2.2 User B: Medical device companies
        • 5.18.3.2.2.1 Implementation
        • 5.18.3.2.2.2 Impact
      • 5.18.3.2.3 User C: Research institutes
        • 5.18.3.2.3.1 Implementation
        • 5.18.3.2.3.2 Impact
      • 5.18.3.2.4 User D: Outsourced life science organizations
        • 5.18.3.2.4.1 Implementation
        • 5.18.3.2.4.2 Impact

6 IMPACT OF 2025 US TARIFF-OVERVIEW

• 6.1 INTRODUCTION
• 6.2 KEY TARIFF RATES
• 6.3 PRICE IMPACT ANALYSIS
• 6.4 IMPACT ON COUNTRY/REGION
  • 6.4.1 US
  • 6.4.2 EUROPE
  • 6.4.3 ASIA PACIFIC
• 6.5 IMPACT ON END-USE INDUSTRIES

7 LIFE SCIENCE ANALYTICS MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 DESCRIPTIVE ANALYTICS
  • 7.2.1 ADVANCED VISUAL DATA EXPLORATION AND SUPPORT FOR INNOVATION TO DRIVE DEMAND
• 7.3 PREDICTIVE ANALYTICS
  • 7.3.1 SIMULATION DEVELOPMENT FOR PREDICTING FUTURE TRENDS TO PROPEL MARKET GROWTH
• 7.4 PRESCRIPTIVE ANALYTICS
  • 7.4.1 REAL-TIME ANALYSIS FOR IMPROVED DECISION-MAKING TO SUPPORT MARKET GROWTH

8 LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT

• 8.1 INTRODUCTION
• 8.2 SERVICES
  • 8.2.1 MANAGED SERVICES
    • 8.2.1.1 Analytical services
      • 8.2.1.1.1 Focus on expediting approvals and product launches to drive growth
    • 8.2.1.2 Consulting services
      • 8.2.1.2.1 Support for R&D, process development, and other workflow processes to drive market
  • 8.2.2 PROFESSIONAL SERVICES
    • 8.2.2.1 Training & implementation services
      • 8.2.2.1.1 Stringent regulations, increasing competition, and need for skill development to propel demand
    • 8.2.2.2 Maintenance & support services
      • 8.2.2.2.1 Rising complexity of analytical technologies and expanding research needs to support market growth
    • 8.2.2.3 Other professional services
• 8.3 SOFTWARE
  • 8.3.1 ON-PREMISES
    • 8.3.1.1 Provision of multivendor architecture and security benefits to drive market
  • 8.3.2 CLOUD-BASED
    • 8.3.2.1 Real-time analysis and elimination of purchasing costs for software & hardware to drive adoption
  • 8.3.3 SAAS-BASED
    • 8.3.3.1 Increasing adoption of digital solutions and advantages of cloud-based models to drive growth

9 LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 RESEARCH & DEVELOPMENT
  • 9.2.1 CLINICAL TRIALS
    • 9.2.1.1 Laboratory services
      • 9.2.1.1.1 Better accuracy, efficiency, and data interpretation to support demand for lab services
    • 9.2.1.2 Patient recruitment services
      • 9.2.1.2.1 Need for better candidate identification and enrollment forecasting to propel market growth
    • 9.2.1.3 Site identification services
      • 9.2.1.3.1 Benefits in locating ideal trial sites and interpreting data to support adoption
    • 9.2.1.4 Other clinical trial services
    • 9.2.1.5 Life science analytics market for clinical trials, by phase
    • 9.2.1.6 PHASE I
      • 9.2.1.6.1 Strong pipeline of pharmaceutical companies to propel market growth
    • 9.2.1.7 PHASE II
      • 9.2.1.7.1 Extended duration of phase II studies to create growth opportunities for CROs
    • 9.2.1.8 PHASE III
      • 9.2.1.8.1 Rising trial expenditure to drive demand for cost-effective clinical research services
  • 9.2.2 PRECLINICAL & DRUG DISCOVERY
    • 9.2.2.1 Ability to assist researchers in process innovation and decision support to drive adoption
• 9.3 COMMERCIAL ANALYTICS
  • 9.3.1 SALES & MARKETING SUPPORT
    • 9.3.1.1 Rising analysis of digital marketing effectiveness to drive adoption
  • 9.3.2 MARKET ACCESS
    • 9.3.2.1 Focus on strategic pricing, reimbursement, and policy changes to support market growth
  • 9.3.3 RWE & VALUE EVIDENCE
    • 9.3.3.1 Increased data integration, partnerships, and technological to propel use of RWE
  • 9.3.4 ENGAGEMENT SERVICES
    • 9.3.4.1 Need for better patient engagement, digital advancements, and AI integration to propel market
• 9.4 REGULATORY COMPLIANCE
  • 9.4.1 STRINGENT REQUIREMENTS FOR COMPLIANCE ADHERENCE TO DRIVE ADOPTION
• 9.5 MANUFACTURING & SUPPLY CHAIN OPTIMIZATION
  • 9.5.1 RISING NEED FOR REDUCING LOGISTICS COSTS TO SUPPORT MARKET GROWTH
• 9.6 SAFETY
  • 9.6.1 PHARMACOVIGILANCE
    • 9.6.1.1 Monitoring of drug trials and medication programs to fuel market uptake
  • 9.6.2 MEDICAL DEVICE SAFETY
    • 9.6.2.1 Stringent safety standards, rigorous risk assessments, and robust quality control to drive demand
  • 9.6.3 DIAGNOSTIC VIGILANCE
    • 9.6.3.1 Continuous monitoring, integration of diverse data sources, and ongoing education to enhance accuracy and thoroughness

10 LIFE SCIENCE ANALYTICS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.2.1 RISING NEED FOR INNOVATIVE THERAPIES TO DRIVE ANALYTICS USAGE IN PRODUCT DEVELOPMENT
• 10.3 MEDICAL DEVICE COMPANIES
  • 10.3.1 ADOPTION OF DATA ANALYTICS FOR DEVICE COMMERCIALIZATION TO DRIVE MARKET
• 10.4 RESEARCH CENTERS
  • 10.4.1 NEED FOR ANALYZING LARGE VOLUMES OF DATA TO SUPPORT MARKET GROWTH
• 10.5 OUTSOURCED LIFE SCIENCE ORGANIZATIONS
  • 10.5.1 RISING R&D OUTSOURCING BY LIFE SCIENCE COMPANIES TO DRIVE MARKET

11 LIFE SCIENCE ANALYTICS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 11.2.2 US
    • 11.2.2.1 Established economy and increasing R&D expenditure to drive adoption of analytical solutions
  • 11.2.3 CANADA
    • 11.2.3.1 Rising need for data standardization in life sciences to fuel uptake
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Growing R&D investments by pharmaceutical & biotechnology companies to drive market
  • 11.3.3 FRANCE
    • 11.3.3.1 Growing government support for adoption of AI & big data analytics to drive market
  • 11.3.4 UK
    • 11.3.4.1 Rising clinical trial activity to drive uptake of life science analytics solutions
  • 11.3.5 ITALY
    • 11.3.5.1 Growing number of drug approvals to drive uptake of analytics solutions
  • 11.3.6 SPAIN
    • 11.3.6.1 Surging government investments focusing on personalized medicine to drive growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 11.4.2 JAPAN
    • 11.4.2.1 Growing government support for clinical R&D activities to drive adoption
  • 11.4.3 CHINA
    • 11.4.3.1 Growth in life science industry to support adoption of solutions
  • 11.4.4 INDIA
    • 11.4.4.1 Rising R&D expenditure and drug development to support market growth
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 11.5.2 BRAZIL
    • 11.5.2.1 Brazil to dominate life science analytics market in Latin America
  • 11.5.3 MEXICO
    • 11.5.3.1 Growing prominence of startups and rising R&D activity to propel market
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Rising investments, advancements, and developing healthcare infrastructure to drive market
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LIFE SCIENCE ANALYTICS MARKET
• 12.3 REVENUE ANALYSIS
• 12.4 MARKET SHARE ANALYSIS
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Type footprint
    • 12.5.5.4 Application footprint
    • 12.5.5.5 Component footprint
    • 12.5.5.6 End user footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING
• 12.7 BRAND/SOFTWARE COMPARATIVE ANALYSIS
• 12.8 COMPANY VALUATION AND FINANCIAL METRICS
• 12.9 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF LIFE SCIENCE ANALYTICAL VENDORS
• 12.10 COMPETITIVE SCENARIO
  • 12.10.1 PRODUCT LAUNCHES & ENHANCEMENTS
  • 12.10.2 DEALS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 ORACLE
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products & services offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches & enhancements
      • 13.1.1.3.2 Deals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 MERATIVE
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products & services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Deals
      • 13.1.2.3.2 Other developments
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 SAS INSTITUTE INC.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products & services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches & enhancements
      • 13.1.3.3.2 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 ACCENTURE
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product launches & enhancements
      • 13.1.4.3.2 Deals
      • 13.1.4.3.3 Other developments
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 IQVIA INC.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products & services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product launches & enhancements
      • 13.1.5.3.2 Deals
      • 13.1.5.3.3 Other developments
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Right to win
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 COGNIZANT
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products & services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches & enhancements
      • 13.1.6.3.2 Deals
  • 13.1.7 WIPRO
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products & services offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Deals
  • 13.1.8 VERADIGM LLC
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products & services offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product launches & enhancements
    • 13.1.8.4 Recent developments
      • 13.1.8.4.1 Deals
  • 13.1.9 OPTUM, INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products & services offered
  • 13.1.10 MICROSOFT
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products & services offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Product launches & enhancements
      • 13.1.10.3.2 Deals
  • 13.1.11 MAXISIT
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products & services offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product launches & enhancements
  • 13.1.12 EXLSERVICE HOLDINGS, INC.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products & services offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product launches & enhancements
      • 13.1.12.3.2 Deals
  • 13.1.13 INOVALON
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products & services offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Product launches & enhancements
      • 13.1.13.3.2 Deals
  • 13.1.14 CITIUSTECH INC.
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products & services offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Product launches & enhancements
      • 13.1.14.3.2 Deals
      • 13.1.14.3.3 Expansions
  • 13.1.15 SAAMA
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products & services offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Product launches & enhancements
    • 13.1.15.4 Recent developments
      • 13.1.15.4.1 Deals
      • 13.1.15.4.2 Other developments
  • 13.1.16 AXTRIA
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products & services offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Product launches & enhancements
      • 13.1.16.3.2 Deals
      • 13.1.16.3.3 Expansions
  • 13.1.17 CLARIVATE
    • 13.1.17.1 Business overview
    • 13.1.17.2 Products & services offered
    • 13.1.17.3 Recent developments
      • 13.1.17.3.1 Product launches & enhancements
      • 13.1.17.3.2 Deals
  • 13.1.18 THOUGHTSPHERE
    • 13.1.18.1 Business overview
    • 13.1.18.2 Products & services offered
  • 13.1.19 THOUGHTSPOT INC.
    • 13.1.19.1 Business overview
    • 13.1.19.2 Products & services offered
    • 13.1.19.3 Recent developments
      • 13.1.19.3.1 Product launches & enhancements
      • 13.1.19.3.2 Deals
  • 13.1.20 SALESFORCE, INC.
    • 13.1.20.1 Business overview
    • 13.1.20.2 Products & services offered
    • 13.1.20.3 Recent developments
      • 13.1.20.3.1 Product launches & enhancements
      • 13.1.20.3.2 Deals
• 13.2 OTHER PLAYERS
  • 13.2.1 GOOGLE LLC
  • 13.2.2 AMAZON WEB SERVICES, INC.
  • 13.2.3 VEEVA SYSTEMS
  • 13.2.4 ELSEVIER
  • 13.2.5 KOMODO HEALTH, INC.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS